Aspira Women’s Health

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer will be available for 1x1 meetings with investors on September 17, 2020.  Conference details are as follows:

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference

Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results

Aspira Women’s Health Reports Second Quarter 2020 Financial Results

AUSTIN, Texas, July  31, 2020  (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th

AUSTIN, Texas, July  01, 2020  (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares of ASPIRA's common stock in a private placement at a price of $3.50 per share.

Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million

Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.

Why Vermillion's Stock Is Trading Higher Today

AUSTIN, Texas, June  10, 2020  (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence of COVID-19 antibodies. Our Laboratory has also completed validation of several additional oncology biomarkers.  Both the COVID-19 antibody test and additional biomarkers will be used in an ASPIRA pelvic mass risk assessment pre-surgery workup.

Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers

AUSTIN, Texas, June  09, 2020  (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020, according to a preliminary list of additions posted on June 5, 2020.

Vermillion Set to Join Russell 3000® Index

Vermillion's (VRML) CEO Valerie Palmieri on Q1 2020 Results - Earnings Call Transcript

Conference Call scheduled for today, May 14th at 4:30 p.m. ET Conference Call scheduled for today, May 14th at 4:30 p.m. ET

Vermillion Reports First Quarter 2020 Financial Results

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2019 Results - Earnings Call Transcript

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q3 2019 Results - Earnings Call Transcript

Vermillion's (VRML) CEO Valerie Palmieri on Q2 2019 Results - Earnings Call Transcript

Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2018 Results - Earnings Call Transcript

News for Aspira Women’s Health Stock (VRML)